OmniComm's TrialMaster Added to Kendle's Suite of eClinical Solutions in Multi-Year Agreement
Fort Lauderdale, FL-September 30, 2009
In a multi-year enterprise-wide agreement Kendle will add OmniComm’s TrialMaster EDC solution to its current eClinical offerings.
“Efficient delivery of high-quality data is critical to Kendle’s continued success as a leading provider of clinical data management services,” said John Fontenault, Executive Director and Global Head, Clinical Data Management and Technology. "The addition of the TrialMaster EDC solution to our existing offerings supports Kendle’s focus on providing our global biopharmaceutical customers with cost-effective access to the best eClinical solutions to accelerate their Phase I through IV clinical trials. The TrialMaster platform offers the right mix of functionality to streamline the study development process and drive efficient study operations.”
"We are excited to be working with Kendle to meet the needs of its diverse customer base," said Stephen Johnson, COO of OmniComm Systems. "Kendle is one of the largest and most respected and successful top-tier global CROs with extensive eClinical experience, having conducted more than 250 trials utilizing EDC technologies to expedite the clinical trials process. We look forward to providing them the eClinical solutions and services needed to support their continued delivery of best-in-class clinical development services to their customers.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
MariTide Shows Up to 20% Weight Loss in Phase II Trial for Obesity, Type 2 Diabetes
June 24th 2025In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained weight loss of up to 20% in adults with obesity, with or without type 2 diabetes, alongside notable improvements in glycemic control, supporting its advancement to Phase III studies as a potential once-monthly treatment option.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
